Financial Performance - Second quarter sales increased 4.1% year-over-year to $38.6 billion, with a 4.7% increase on a constant currency basis[5] - Adjusted earnings per share (EPS) decreased 47.3% to $0.63 compared to $1.20 in the year-ago quarter[11] - Net loss for the second quarter was $2.9 billion, a 51.7% decrease from a net loss of $5.9 billion in the year-ago quarter[9] - Operating loss for the second quarter was $5.6 billion, an improvement from a loss of $13.2 billion in the year-ago quarter[7] - The net loss attributable to Walgreens Boots Alliance for the three months ended February 28, 2025, was $2,853 million, a reduction from a net loss of $5,908 million in the same period last year, reflecting a decrease of 51.7%[51] - Net loss for the six months ended February 29, 2025, was $4,640 million, a significant improvement from a net loss of $12,600 million in the same period of 2024, representing a reduction of approximately 63.2%[55] - The diluted net loss per common share (GAAP) for the six months ended February 28, 2025, was $(3.61), compared to $(6.93) for the same period in 2024, indicating an improvement of 47.9%[68] Sales and Revenue - U.S. Retail Pharmacy segment sales increased 5.3% to $30.4 billion, with comparable sales up 8.2%[21] - International segment sales were $6.1 billion, a 0.6% increase, with a 4.1% increase on a constant currency basis[26] - For the three months ended February 28, 2025, Walgreens Boots Alliance reported sales of $38,588 million, an increase from $37,052 million for the same period in 2024, representing a growth of 4.1%[51] - Total sales for the three months ended February 28, 2025, were $38,588 million, compared to $37,052 million for the same period in 2024, representing a year-over-year increase of approximately 4.1%[73] - The U.S. Retail Pharmacy segment reported sales of $30,380 million for the three months ended February 28, 2025, compared to $28,861 million for the same period in 2024, marking an increase of about 5.3%[73] Cash Flow and Assets - Free cash flow was negative $418 million, a $192 million improvement compared to the year-ago quarter[12] - Cash flows from operating activities showed a net cash used of $339 million for the six months ended February 29, 2025, compared to $918 million for the same period in 2024, indicating a 63.1% improvement[55] - The company reported a net cash provided by investing activities of $342 million for the six months ended February 29, 2025, down from $902 million in the prior year, reflecting a decrease of 62.1%[55] - Total assets decreased to $70,216 million as of February 28, 2025, down from $81,037 million as of August 31, 2024, representing a decline of 13.4%[52] - Walgreens Boots Alliance's cash and cash equivalents decreased to $702 million as of February 28, 2025, down from $1,319 million as of August 31, 2024, a decline of 46.9%[52] Strategic Initiatives - The company is withdrawing fiscal 2025 guidance due to a pending acquisition by Sycamore Partners[3] - The merger with Sycamore Partners is expected to close in the fourth quarter of calendar year 2025, pending approvals[35] - The company aims to enhance its business strategies and is currently undergoing a strategic review, which includes potential mergers and acquisitions[37] - Walgreens Boots Alliance is focused on cost-saving initiatives and growth strategies, including the Footprint Optimization Program, to improve financial performance moving forward[37] Impairments and Charges - The company reported a goodwill impairment charge of $3,653 million for the three months ended February 28, 2025, consistent with the charge of $12,369 million in the same period last year[51] - The company incurred impairment of goodwill, intangibles, and long-lived assets of $5,343 million for the three months ended February 28, 2025, compared to $13,090 million for the same period in 2024, a reduction of 59.1%[67] - The company recognized impairment of goodwill, intangibles, and long-lived assets of $3,252 million for the three months ended February 28, 2025[75] Operating Performance - The company's gross profit for the six months ended February 28, 2025, was $13,714 million, slightly down from $13,811 million in the prior year, indicating a decrease of 0.7%[51] - The adjusted gross profit for the three months ended February 28, 2025, was $6,963 million, slightly down from $7,068 million in the same period of 2024, indicating a decrease of about 1.5%[73] - The adjusted operating income for the three months ended February 28, 2025, was $785 million, down from $900 million in the same period of 2024, reflecting a decline of approximately 12.8%[74] - U.S. Healthcare segment reported an operating loss of $3,304 million for the three months ended February 28, 2025, compared to a loss of $13,059 million for the same period in 2024[75] - Adjusted EBITDA for the U.S. Healthcare segment was $158 million for the three months ended February 28, 2025, up from $17 million in the same period last year[75] Other Financial Metrics - The company incurred acquisition-related amortization expenses of $250 million for the three months ended February 28, 2025, compared to $270 million for the same period in 2024[74] - The effective tax rate (GAAP) for the three months ended February 28, 2025, was 5.0%, compared to 6.0% for the same period in 2024[79] - Adjusted effective tax rate excluding adjusted equity earnings in Cencora was 27.7% for the three months ended February 28, 2025, compared to (29.4)% for the same period in 2024[79] - The company recognized a pre-tax non-controlling interest benefit due to the amendment of the VillageMD Secured Loan, which is not indicative of normal operating performance[72] - The company made incremental pension contributions of $379 million during the three months ended February 29, 2024, as part of a bulk annuity policy acquisition[80]

Group 1 - Walgreens Boots Alliance, Inc. (WBA) is set to release its second-quarter earnings results on April 8, with analysts expecting earnings of 53 cents per share, a decrease from $1.2 per share in the same period last year [1] - The projected quarterly revenue for Walgreens is $38.0 billion, an increase from $37.05 billion a year earlier [1] - On March 6, Walgreens Boots Alliance entered into an agreement to be acquired by private equity firm Sycamore Partners [1] Group 2 - Walgreens shares closed at $10.71, reflecting a gain of 0.3% [2] - Recent analyst ratings show a mix of downgrades and price target adjustments, with Deutsche Bank downgrading the stock from Hold to Sell and reducing the price target from $11 to $9 [3] - Truist Securities maintained a Hold rating while lowering the price target from $13 to $12, and RBC Capital raised its price target from $9 to $12 while maintaining a Sector Perform rating [3]

Walgreens Boots Alliance, Inc. WBA will release earnings results for the second quarter, before the opening bell on Tuesday, April 8.Analysts expect the company to report quarterly earnings at 53 cents per share, down from $1.2 per share in the year-ago period. According to data from Benzinga Pro, Walgreens projects quarterly revenue at $38.0 billion, compared to $37.05 billion a year earlier.On March 6, Walgreens Boots Alliance entered an agreement to be acquired by private equity firm Sycamore Partners.Wi ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.Below are the ratings of the most accurate analysts for three high-yield ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Walgreens Boots Alliance, Inc. regarding a class action lawsuit due to alleged misleading statements and regulatory violations during the specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from April 2, 2020, to January 16, 2025 [3]. - Allegations include that Walgreens engaged in widespread violations of federal law related to prescription medication dispensation and reimbursement, undermining their claims of improved regulatory compliance [3]. - The lawsuit claims that Walgreens' revenues from prescription medication sales were unsustainable due to unlawful conduct, leading to potential regulatory scrutiny and reputational harm [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of March 31, 2025, to participate in potential recovery [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock value [5].

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between April 2, 2020 and January 16, 2025, both dates inclusive (the "Class Period"), of the important March 31, 2025 lead plaintiff deadline. SO WHAT: If you purchased Walgreens common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Walgreens Boots Alliance, Inc. regarding a class action lawsuit due to alleged misleading statements and regulatory violations during the specified class period [1][2]. Summary by Sections Allegations - The complaint alleges that Walgreens engaged in widespread violations of federal law related to prescription medication dispensation and reimbursement, contrary to its claims of improved regulatory compliance [1]. - It is claimed that the company's conduct would lead to increased regulatory scrutiny, civil liability, and reputational damage [1]. - The revenues from prescription medication sales are described as unsustainable due to their association with unlawful practices [1]. - Consequently, Walgreens' public statements are asserted to have been materially false and misleading throughout the relevant period [1]. Class Action Details - The class period for the lawsuit is defined as April 2, 2020, to January 16, 2025 [1]. - Shareholders are encouraged to register for the class action by the deadline of March 31, 2025, to potentially be appointed as lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring system regarding the case's progress [2]. Law Firm Background - The Gross Law Firm is recognized nationally for its class action work, focusing on protecting investors from deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflate stock prices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Walgreens Boots Alliance, Inc. common stock between April 2, 2020, and January 16, 2025, of the March 31, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Walgreens common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by March 31, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Walgreens failed to disclose widespread violations of federal law regarding prescription medication dispensation and reimbursement during the Class Period [5]. - It is claimed that Walgreens' conduct posed a heightened risk of regulatory scrutiny, civil liability, and reputational harm, leading to materially false and misleading public statements [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the unsustainable nature of Walgreens' revenues from unlawful conduct [5].

Core Viewpoint - A class action securities lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged securities fraud affecting investors between April 2, 2020, and January 16, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Walgreens made false statements regarding its commitment to regulatory compliance while continuing to violate federal laws related to prescription medication dispensation [2]. - It is alleged that Walgreens' unlawful conduct would lead to increased regulatory scrutiny, civil liability, and reputational damage [2]. - The complaint asserts that Walgreens' revenues from prescription medication sales were unsustainable due to their reliance on illegal activities, rendering the company's public statements materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until March 31, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Walgreens has agreed to pay $2.8 million to settle allegations of submitting inflated prices to Medicaid programs in Massachusetts and Georgia for generic medications [1][2]. Group 1: Settlement Details - The settlement resolves a qui tam lawsuit alleging violations of the federal, Massachusetts, and Georgia False Claims Acts by Walgreens [1]. - The allegations state that between 2008 and 2023, Walgreens pharmacies submitted higher usual and customary prices for certain generic medications, leading to overpayments by Medicaid programs [2]. Group 2: False Claims Act Context - The False Claims Act imposes treble damages and penalties for knowingly false claims against the United States [3]. - In the fiscal year ending September 30, 2024, settlements and judgments under the False Claims Act exceeded $2.9 billion, with 588 settlements and judgments involving whistleblowers filing 979 qui tam lawsuits [3]. Group 3: Healthcare Industry Impact - Healthcare-related matters, including pharmacies, accounted for $1.67 billion of the total $2.9 billion in False Claims Act settlements and judgments [4]. - The number of qui tam lawsuits filed was the highest in a single year, with the second-highest number of settlements and judgments recorded [4]. Group 4: Previous Allegations Against Walgreens - Walgreens and its parent company, Walgreens Boots Alliance, previously agreed to pay $106.8 million to resolve allegations of billing government healthcare programs for prescriptions that were never dispensed [5]. - The government alleged that from 2009 to 2020, Walgreens received tens of millions of dollars for prescriptions processed but not picked up by beneficiaries [5].